This review discusses the evidence on the use of nivolumab (Opdivo®), a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed death-1 (PD-1) receptor and is indicated:
• In combination with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody ipilimumab (Yervoy®) for the treatment of patients with intermediate- or poor-risk (IPR), previously untreated advanced renal cell carcinoma (RCC)
• In combination with the tyrosine kinase inhibitor (TKI) cabozantinib for the first-line treatment of patients with advanced RCC
• As monotherapy for the treatment of patients with advanced clear-cell RCC after prior antiangiogenic therapy.
Based on these indications, and recent data from international guidelines and large-scale, long-term clinical trials, this review highlights the clinical profile of: nivolumab + ipilimumab as a first-line therapy in IPR patients with advanced RCC; and nivolumab monotherapy in previously treated patients with advanced clear-cell RCC. This resource was created with funding from Bristol-Myers Squibb NZ Ltd.
Please login below to download this issue (PDF)